Yuichi Saito1, MD; Henning Kelbæk2, MD; Bo Xu3, MD; Yasin Hussain1, MD; Richard Anderson4, MD; Volker Schächinger5, MD; Ming Zheng6, MD; William Wijns7, MD; Andreas Baumbach1,8, MD; Alexandra J. Lansky1,8, MD
1. Yale University School of Medicine, New Haven, CT, USA; 2. Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark; 3. Fu Wai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 4. Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom; 5. Medizinische Klinik I, Herz-Thorax Zentrum, Klinikum Fulda, Fulda, Germany; 6. Shanghai MicroPort Medical (Group) Co., Ltd., Shanghai, China; 7. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, and Saolta University Healthcare Group, Galway, Ireland; 8. Barts Heart Centre, London, and Queen Mary University of London, London, United Kingdom
New-generation drug-eluting stents (DES), including both biodegradable and durable polymer stents, are currently recommended as a default strategy in percutaneous coronary intervention (PCI). A meta-analysis of 16 contemporary randomised DES trials demonstrated similar safety and efficacy of biodegradable polymer DES with respect to stent-related coronary events up to a mean follow-up period of 26 months compared to current-generation durable polymer DES, suggesting no clinical benefit of biodegradable polymer at least at two-year follow-up1. The Firehawk® (Shanghai MicroPort® Medical (Group), Co., Ltd., Shanghai, China) is a thin-strut coronary stent with sirolimus and biodegradable polymer complex localised in abluminal grooves ...